公开(公告)号：US20210052603A1

公开(公告)日：2021-02-25

申请号：US17051332

申请日：2019-05-03

Applicant: Emory University ,  Hadasit Medical Research Services and Development Ltd.

Inventor： Raymond F. Schinazi ,  Bryan COX ,  Chofit CHAI ,  Hilla GILADI ,  Eithan GALUN ,  Franck AMBLARD

IPC: A61K31/5513 ,  A61K33/243 ,  A61K31/475 ,  A61K31/015 ,  A61K31/131 ,  A61K45/06 ,  C07D401/10 ,  C07D403/10 ,  C07D413/10 ,  C07D401/12

Abstract: Compounds, compositions and methods for modulating retinoic acid receptor-like orphan receptors (ROR) and associated diseases. Methods for treatment or prophylaxis of metabolic disorders, liver disorders or diseases, including NASH, immune disorders, central nervous system disorders, or cancer are disclosed.

公开(公告)号：US10710968B2

公开(公告)日：2020-07-14

申请号：US16069546

申请日：2017-01-12

Applicant: Hadasit Medical Research Services and Development Ltd.

Inventor： Eyal Yosef Mishani ,  Ofer Shamni ,  Galith Rachel Abourbeh-Gofrit

IPC: A61K51/00 ,  A61M36/14 ,  C07D239/94 ,  A61K45/06 ,  A61P35/00 ,  A61K51/04 ,  C07B59/00 ,  C12Q1/6886

Abstract: Radiolabeled compounds which are erlotinib analogs that feature a radioactive halogen and processes of preparing same are disclosed. Uses of these radiolabeled compounds in radioimaging, for identifying and monitoring a level, distribution and/or mutational status of deregulated EGFR, and/or in radiotherapy, are also disclosed.

公开(公告)号：US20200017484A1

公开(公告)日：2020-01-16

申请号：US16485577

申请日：2018-02-22

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. ,  RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： Or KAKHLON ,  Miguel Enrique WEIL ,  Leonardo Javier SOLMESKY

IPC: C07D409/12 ,  C07D487/08 ,  A61P25/28

Abstract: Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.

公开(公告)号：US20190330303A1

公开(公告)日：2019-10-31

申请号：US16417048

申请日：2019-05-20

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD

Inventor： Abraham RUTENBERG ,  Ronny UZANA ,  Michal LOTEM ,  Arthur MACHLENKIN ,  Galit EISENBERG ,  Tamar PERETZ-YABLONSKY ,  Shoshana FRANKENBURG ,  Roni ENGELSTEIN

IPC: C07K14/705 ,  A61K39/39 ,  A61K45/06 ,  A61K39/395 ,  C07K16/28 ,  A61K35/17 ,  C12N5/0783

Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

公开(公告)号：US10266897B2

公开(公告)日：2019-04-23

申请号：US15914112

申请日：2018-03-07

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Rifaat Safadi

IPC: C07H21/02 ,  C07H21/04 ,  C12Q1/6883 ,  A61K31/7088 ,  A61K45/06 ,  C12N15/113 ,  A61K31/713 ,  A61K31/7105

Abstract: A kit having a means for isolating an immune cell population from a biological sample of a patient; and at least one agent capable of detecting NLGn4 gene product expression level.

公开(公告)号：US20190023664A1

公开(公告)日：2019-01-24

申请号：US16069546

申请日：2017-01-12

Applicant: Hadasit Medical Research Services and Development Ltd.

Inventor： Eyal Yosef MISHANI ,  Ofer SHAMNI ,  Galith Rachel ABOURBEH-GOFRIT

IPC: C07D239/94 ,  C07B59/00 ,  A61K51/04 ,  C12Q1/6886 ,  A61P35/00 ,  A61K45/06

CPC classification number: C07D239/94 ,  A61K45/06 ,  A61K51/0459 ,  A61P35/00 ,  C07B59/002 ,  C07B2200/05 ,  C12Q1/6886 ,  C12Q2600/106

Abstract: Radiolabeled compounds which are erlotinib analogs that feature a radioactive halogen and processes of preparing same are disclosed. Uses of these radiolabeled compounds in radioimaging, for identifying and monitoring a level, distribution and/or mutational status of deregulated EGFR, and/or in radiotherapy, are also disclosed.

公开(公告)号：US20180271950A1

公开(公告)日：2018-09-27

申请号：US15763550

申请日：2016-09-29

Applicant: Hadasit Medical Research Services and Development Ltd. ,  Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Inventor： Amir HAZE ,  Anat BLUMENFELD ,  Dan DEUTSCH

IPC: A61K38/39 ,  A61K45/06

CPC classification number: A61K38/39 ,  A61K38/1825 ,  A61K38/185 ,  A61K38/1858 ,  A61K38/30 ,  A61K45/06 ,  Y02A50/469 ,  A61K2300/00

Abstract: A method of promoting nerve growth or regeneration in a subject in need thereof, wherein the subject is not afflicted with a substantial connective tissue damage, is provided. The method comprises administering to the subject a therapeutically effective amount of full-length amelogenin, thereby promoting nerve growth or regeneration in the subject.

公开(公告)号：US20180216064A1

公开(公告)日：2018-08-02

申请号：US15748541

申请日：2016-07-28

Applicant: Hadasit Medical Research Services and Development Ltd.

Inventor： Benjamin Eithan REUBINOFF ,  Orna SINGER

IPC: C12N5/079 ,  A61K35/30 ,  A61K9/00 ,  A61P27/02

CPC classification number: C12N5/0621 ,  A61K9/0051 ,  A61K35/30 ,  A61P27/02 ,  C12N2500/38 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2502/13 ,  C12N2506/02 ,  C12N2533/52 ,  C12N2533/54

Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGFβ superfamily.

公开(公告)号：US20180202001A1

公开(公告)日：2018-07-19

申请号：US15914112

申请日：2018-03-07

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Rifaat SAFADI

IPC: C12Q1/6883 ,  A61K31/713 ,  A61K31/7105 ,  C12N15/113 ,  A61K45/06 ,  A61K31/7088

CPC classification number: C12Q1/6883 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12Q2600/158

Abstract: A kit having a means for isolating an immune cell population from a biological sample of a patient; and at least one agent capable of detecting NLGn4 gene product expression level.

公开(公告)号：US09993497B2

公开(公告)日：2018-06-12

申请号：US14758603

申请日：2013-12-30

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. ,  B.G. NEGEV TECHNOLOGIES & APPLICATIONS LTD.

Inventor： Smadar Cohen ,  Yaron Ilan ,  Eyal Shteyer ,  Ami Ben-Ya'acov

IPC: A61K31/734 ,  A61K31/167 ,  A61K9/00 ,  A61K45/06

CPC classification number: A61K31/734 ,  A61K9/0053 ,  A61K31/167 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.